Titel: | Allergen immunotherapy during the COVID-19 pandemic : A survey of the German Society for Allergy and Clinical Immunology |
Autor: | Pfaar, Oliver |
Weitere Verfasser: | Hamelmann, Eckard; Klimek, Ludger; Taube, Christian; Vogelberg, Christian; Wagenmann, Martin; Werfel, Thomas; Worm, Margitta |
Veröffentlicht: | 2023 |
URI: | https://archiv.ub.uni-marburg.de/es/2023/0039 |
URN: | urn:nbn:de:hebis:04-es2023-00398 |
DOI: | https://doi.org/10.1002/clt2.12134 |
DDC: | 610 Medizin |
Publikationsdatum: | 2023-04-04 |
Lizenz: | https://creativecommons.org/licenses/by/4.0 |
Schlagwörter: |
---|
safety, COVID‐19, allergen immunotherapy, SARS‐CoV‐2, pandemic, survey |
Summary:
Background:
When the coronavirus pandemic 2019 (COVID-19) emerged, concerns were also raised regarding the safety of allergen immunotherapy (AIT). The German Society for Allergology and Clinical Immunology (DGAKI) conducted a survey to collect real-world data on the daily routine of administering subcutaneous AIT (SCIT) and sublingual AIT (SLIT) during the COVID-19 pandemic.
Methods:
A web-based retrospective survey using the online platform survio with 26 standardized questions was used to survey physicians treating allergic patients during the pandemic.
Results:
Three hundred and forty-five physicians who regularly offer and perform AIT in German-speaking countries responded to the questions. 70.4% of the respondents stated that they regularly initiated and dosed up SCIT for inhalant allergies (41.4% venom-SCIT, 73.6% SLIT), and 85.2% of the respondents stated that they continued SCIT for inhalant allergies during the maintenance phase in a regular way (59.1% venom-SCIT, 90.4% SLIT) in healthy patients without current symptoms indicating an infection with COVID-19. With regard to tolerability, there was no evidence for increased occurrence of adverse events in patients without current symptoms of COVID-19 infection during the pandemic.
Conclusions:
This retrospective study demonstrated adherence to national and international position papers of AIT during the COVID-19 pandemic in German-speaking countries. Besides, the survey has confirmed a good tolerability of AIT for both SCIT and SLIT.
![]() | Das Dokument ist im Internet frei zugänglich - Hinweise zu den Nutzungsrechten |